Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia

Andrew Lee; Suneet Sandhu; Louise Imlay-Gillespie; Stephen Mulligan; Stephen Shumack

doi:10.1111/ajd.12615

Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia

Australas J Dermatol. 2017 Nov;58(4):e240-e242. doi: 10.1111/ajd.12615. Epub 2017 Mar 13.

Authors

Andrew Lee^{1

2}, Suneet Sandhu^{3

4}, Louise Imlay-Gillespie³, Stephen Mulligan^{2

3

4}, Stephen Shumack^{1

2}

Affiliations

¹ Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
² Sydney Medical School Northern, University of Sydney, Sydney, New South Wales, Australia.
³ Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁴ Northern Blood Research Centre, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

PMID: 28295171
DOI: 10.1111/ajd.12615

Abstract

We present the case of a 51-year-old man who developed paraneoplastic pemphigus (PNP) in the context of chronic lymphocytic leukemia (CLL). His CLL was successfully controlled with ibrutinib. Concurrently, there was significant improvement of his PNP, suggesting that ibrutinib may be a very useful addition to the treatment options in this potentially life-threatening autoimmune disorder.

Keywords: PAMS; chronic lymphocytic leukemia; ibrutinib; paraneoplastic pemphigus.

Publication types

Case Reports

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Antineoplastic Agents / therapeutic use*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Middle Aged
Paraneoplastic Syndromes / etiology*
Pemphigus / etiology*
Piperidines
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine